Fig. 2: Foxk1 and Foxk2 extend the cardiomyocyte proliferative window.
From: Foxk1 and Foxk2 promote cardiomyocyte proliferation and heart regeneration
A Experimental design: neonatal mice were administered AAV9-GFP, AAV9-Foxk1, or AAV9-Foxk2 on postnatal day 1 (P1) to overexpress Foxk1 or Foxk2 specifically in cardiomyocytes. Heart tissue was subsequently collected at P14. B Western blot analysis of FOXK1 and FOXK2 expression in P14 mouse cardiomyocytes (n = 3 mice per group). C H&E-stained heart sections (n = 5 mice per group). D, E WGA staining of heart tissue sections and quantitative analysis of the cross-sectional area of cardiomyocytes (CM size) (n = 3 per group). F Analysis of total cardiomyocyte counts per heart across different experimental groups (n = 6 per group). G Representative images of cardiomyocytes isolated from the hearts of mice treated with AAV9-Foxk1 or AAV9-Foxk2 and quantification of nucleation at P14 (n = 3 per group). H–J Representative images of co-immunostaining and quantitative analysis for α-actinin (red) and Aurora B (green, indicated by yellow arrows) (H), pH3 (green) (I), and Ki67 (green) (J) in heart tissue sections (n = 4 per group). Data are presented as mean ± SEM. p values were determined by one-way ANOVA with Bonferroni multiple comparisons test (E, F, and H–J) and two-way ANOVA with Bonferroni multiple comparisons test (G). Source data are provided as a Source Data file.
